Study reveals increased risk of arrhythmias including atrial fibrillation after COVID-19

Sweden: A recent study published in the European Heart Journal Open has revealed an increased risk of cardiac arrhythmias following COVID-19, particularly in elderly vulnerable individuals, and those with severe COVID-19. 

Individuals infected with COVID-19 are also at an increased risk of suffering from heart rhythm disturbances, such as atrial fibrillation, according to a study at Umeå University, Sweden, which is one of the largest studies of its kind in the world.

“The results underline the importance of both being vaccinated against COVID-19 and that the healthcare system identifies people at increased risk of this type of complications so that the correct diagnosis is made and appropriate treatment is started in time,” says Ioannis Katsoularis, first author of the study and cardiologist at University Hospital of Northern Sweden in Umeå.

The researchers were able to show that those who had been ill with COVID-19 could also suffer from heart rhythm disturbances, both in the form of so-called tachycardias, when the heart rate is high, and bradyarrhythmias, when the heart is slow so that a pacemaker is sometimes needed.

The study shows that the risk of atrial fibrillation and flutter was increased up to two months after infection. In the first month, the risk was twelve times greater than for people who did not suffer from COVID-19 infection.

Even the risk of a specific subset of tachycardias, paroxysmal supraventricular tachycardiaswas elevated up to 6 months after the infection and was five times greater in the first month. For the bradyarrhythmias, the risk was increased up to 14 days after the infection and was three times greater in the first month compared to subjects without COVID-19. Previous research in this area had not focused as much on which individuals are most at risk.

“We found that the risks were higher in older individuals, individuals with severe COVID-19 and during the first wave of the pandemic. We could also see that unvaccinated people were at higher risk than vaccinated people. Overall, the severity of the infection was the strongest risk factor,” says Anne-Marie Fors Connolly, who leads the research group at Umeå University that is behind the study.

In the study, information from large national registers was cross-checked. All people who tested positive for the virus in Sweden from the start of the pandemic until May 2021 were included, but also a comparison group of individuals without a positive test for the virus. Over one million individuals with COVID-19 and over four million control individuals were included in this nationwide study, which is one of the largest of its kind in the world. Researchers at Umeå University have previously shown that COVID-19 leads to an increased risk of blood clots, myocardial infarction and stroke.

Reference:

Ioannis Katsoularis, Hanna Jerndal, Sebastian Kalucza, Krister Lindmark, Osvaldo Fonseca-Rodríguez, Anne-Marie Fors Connolly, Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study, European Heart Journal Open, Volume 3, Issue 6, November 2023, oead120, https://doi.org/10.1093/ehjopen/oead120.

Powered by WPeMatico

A nomogram may predict conversion of laparoscopic surgery to open surgery for choledocholithiasis.

Approximately 3-18% of gallbladder stone patients have secondary choledocholithiasis. Laparotomy was previously the standard treatment but required large abdominal incisions and caused postoperative infections, pain, and longer hospital stays. Laparoscopic common bile duct exploration (LCBDE) surgery is now favored as it is less invasive and has a lower risk of infection. Those with common bile duct (CBD) stones also have intrahepatic bile duct (IHD) stones. Laparoscopic hepatectomy (LH) may be safe for those with IHD stones.

Yitao Zheng and colleagues, in a recent study published in BMC Surgery, said, We developed a nomogram to predict conversion to open surgery in laparoscopic surgery for choledocholithiasis, which aids surgeons in planning surgery and timely converting to laparotomy during surgery to minimize the risk of harm to the patient.

Laparoscopic surgery effectively treats common bile duct stones, but high surgeon requirements and conversion to laparotomy risk exist. Our study established a nomogram model to predict the conversion of laparoscopic to laparotomy for choledocholithiasis.

A total of 867 choledocholithiasis patients who underwent laparoscopic surgery were randomly divided into a training and a validation group. A logistic regression analysis-based nomogram was constructed, and its predictive performance was evaluated using AUC, calibration curve, and DCA (decision curve analysis).

Key findings from the study are:

  • The nomogram included Previous upper abdominal surgery, maximum diameter of stone ≥12 mm, medial wall of the duodenum stone,
  • gallbladder wall and CBD wall thickening, stone size/CBD size ≥0.75, and simultaneous laparoscopic hepatectomy.
  • The AUC values were 0.813 and 0.804 in the training and validation groups, respectively.
  • The calibration curve presented excellent consistency between the nomogram predictions and actual observations.
  • DCA presented a positive net benefit for the nomogram.

In our study, 25 out of 41 conversion surgeries for dense abdominal adhesions were due to PUAS. In our nomogram, stones in the medial wall of the duodenum scored higher with 86 points.

The maximum stone diameter was the transverse diameter perpendicular to the CBD wall. A large ratio increases the difficulty of stone removal. Removing IHD stones is more challenging than liver neoplasm due to the risk of liver inflammation, perihepatic adhesions, and anatomical distortion, the author writes.

Reference:

Zheng, Y et al. A nomogram to predict conversion of laparoscopic surgery to laparotomy for Choledocholithiasis. BMC Surg 23, 372 (2023).

 

Powered by WPeMatico

Healthful Vegetarian diet may improve insomnia, finds study

A recent cohort study, the Tzu Chi Health Study, sheds light on the potential link between dietary patterns and insomnia risk, uncovering intriguing findings about the benefits of plant-based diets in reducing the likelihood of developing insomnia. This study was published in the European Journal Of Clinical Nutrition by Zuo Hua Gan and colleagues.

Researchers aimed to explore whether plant-based diets, specifically vegetarianism, could influence the risk of insomnia. Over 5,800 participants without prior insomnia were enrolled in the study from 2007 to 2009 and followed up until 2018. Two distinct dietary classification methods were employed: traditional categorization into vegetarians and non-vegetarians, and a Healthful Plant-Based Index (hPDI) to gauge adherence to plant-based dietary patterns. Incident cases of insomnia were tracked by linking participant data with the National Health Insurance Research Database (NHIRD).

Throughout 55,562 person-years of follow-up, 464 new cases of insomnia were identified. The study revealed noteworthy associations between plant-based diets and insomnia risk. Male vegetarians exhibited a substantially lower risk of insomnia compared to non-vegetarians, showing hazard ratios (HR) of 0.47 and 0.71 for males and females, respectively. Additionally, among male participants with the highest adherence to the healthful plant-based index (hPDI), there was a notable reduction in insomnia risk (HR 0.50) compared to those in the lowest quintile. Surprisingly, no significant association between adherence to hPDI and insomnia risk was observed in female participants.

The findings underscore a potential protective effect of vegetarianism against insomnia, highlighting the sleep-related benefits of plant-based diets. However, the study also suggests that the relationship between adherence to healthful plant-based diets and insomnia risk might vary by gender, showcasing sex-specific associations.

The study outcomes emphasise the potential additional benefits of plant-based diets beyond their known health advantages. The reduced risk of insomnia among vegetarians hints at the relevance of dietary choices in managing sleep-related issues. Yet, the gender-specific differences in the relationship between plant-based diet adherence and insomnia warrant further investigation.

These findings offer valuable insights into the intricate interplay between diet and sleep health, paving the way for future research exploring the mechanisms underlying these associations and potentially tailoring dietary recommendations for improved sleep outcomes.

Reference:

Gan, Z. H., Chiu, T. H. T., Lin, C.-L., Lin, M.-N., & Kuo, P.-H. Plant-based dietary patterns and risk of insomnia: a prospective study. European Journal of Clinical Nutrition,2023;1–8. https://doi.org/10.1038/s41430-023-01380-x

Powered by WPeMatico

Yoga Nidra practice may improve sleep, memory, and cognition: Study

India: Yoga Nidra practice can improve cognitive processing and night-time sleep, a recent study published in PLOS ONE has revealed. Yoga Nidra is a kind of mindfulness training. 

“Practicing yoga nidra might improve sleep, cognition, learning, and memory, even in novices, “Karuna Datta of the Armed Forces Medical College in India, and colleagues wrote in their pilot study. After a two-week intervention with a cohort of novice practitioners, the researchers found that the percentage of delta-waves in deep sleep increased and that all tested cognitive abilities improved. 

Unlike more active forms of yoga, which focus on physical postures, breathing, and muscle control, yoga nidra guides people into a state of conscious relaxation while they are lying down.

While it has been reported to improve sleep and cognitive ability, those reports were based more on subjective measures than on objective data.

The new study used objective polysomnographic measures of sleep and a battery of cognitive tests.

Measurements were taken before and after two weeks of yoga nidra practice, which was carried out during the daytime using a 20-minute audio recording.

Among other things, polysomnography measures brain activity to determine how long each sleep stage lasts and how frequently each stage occurs.

After two weeks of yoga nidra, the researchers observed that participants exhibited a significantly increased sleep efficiency and percentage of delta-waves in deep sleep.

They also saw faster responses in all cognitive tests with no loss in accuracy and faster and more accurate responses in tasks including tests of working memory, abstraction, fear and anger recognition, and spatial learning and memory tasks.

The findings support previous studies which link delta-wave sleep to improved sleep quality as well as better attention and memory.

The authors believe their study provides objective evidence that yoga nidra is an effective means of improving sleep quality and cognitive performance.

Yoga nidra is a low-cost and highly accessible activity from which many people might therefore benefit.

The authors add: “Yoga nidra practice improves sleep and makes brain processing faster. Accuracy also increased, especially with learning and memory related tasks.”

Reference:

Karuna Datta, Anna Bhutambare, Mamatha V. L., Yogita Narawa, Rajagopal Srinath, Madhuri Kanitkar. Improved sleep, cognitive processing and enhanced learning and memory task accuracy with Yoga nidra practice in novices. PLOS ONE, 2023; 18 (12): e0294678 DOI: 10.1371/journal.pone.0294678.

Powered by WPeMatico

Xpert Ultra important tool for rapid diagnosis of spinal tuberculosis

A recent study revealed promising outcomes for Xpert Ultra, a non-invasive approach in enhancing spinal tuberculosis (STB) diagnosis. The key findings were published in Open Forum Infectious Diseases.

The study was conducted from November 2020 to December 2021 and focused on evaluating the efficacy of Xpert MTB/RIF Ultra, comparing it with traditional Mycobacterium tuberculosis (Mtb) culture and histopathology. 

The study was aimed to refining diagnostic procedures of STB and showed compelling results. Xpert Ultra demonstrated a remarkable sensitivity of 94.7% and an impressive specificity of 100%, outperforming the conventional Mtb culture and histopathology as the reference standard. This breakthrough is poised to transform the landscape of STB diagnosis, when considering the limitations associated with current methods, predominantly reliant on open surgeries for specimen collection.

The prospective diagnostic accuracy study included 31 adult patients exhibiting signs and symptoms of STB. Xpert Ultra’s diagnostic prowess remained consistent across both open and CT-guided biopsy samples, improving the sensitivity and specificity to 100% for open biopsies and 89% and 100%, respectively, for CT-guided ones. However, Mtb culture exhibited a notable specificity gap for CT-guided biopsies, hovering at 43%.

Also, the study found that HIV-1 co-infection did not influence the accuracy of Mtb abundance measures by Xpert Ultra or culture. Xpert Ultra surpassed traditional culture methods for STB diagnosis even in patients concurrently undergoing treatment for pulmonary TB.

The study’s conclusion brings out the ability of Xpert Ultra to detect more STB cases than conventional culture methods, particularly in CT-guided biopsy samples, and maintaining consistent sensitivity for open biopsies, Xpert Ultra emerges as a crucial tool for swift and accurate diagnosis, especially when open surgery is impractical or when simultaneous treatment for pulmonary TB is underway.

Source:

Waters, R., Laubscher, M., Dunn, R. N., Adikary, N., Coussens, A. K., & Held, M. (2023). Higher sensitivity of Xpert MTB/RIF Ultra over TB culture for the diagnosis of spinal tuberculosis using open or CT-guided biopsies. In Open Forum Infectious Diseases. Oxford University Press (OUP). https://doi.org/10.1093/ofid/ofad621

Powered by WPeMatico

Preconception paternal drinking habits can negatively affect fetal development

USA: In an article published in Andrology, the lab of Dr. Michael Golding has demonstrated that it takes much longer than previously believed, longer than a month, for the effects of alcohol consumption to leave the father’s sperm.

Researchers at Texas A&M University have already shown that paternal drinking habits before conception can harm fetal development semen from men who regularly consume alcohol impacting placenta development, fetal alcohol syndrome (FAS)-associated brain and facial defects, and even IVF outcomes.

“When someone is consuming alcohol on a regular basis and then stops, their body goes through withdrawal, where it has to learn how to operate without the chemical present,” said Golding, a professor in the School of Veterinary Medicine & Biomedical Sciences’ Department of Veterinary Physiology & Pharmacology. “What we discovered is that a father’s sperm are still negatively impacted by drinking even during the withdrawal process, meaning it takes much longer than we previously thought for the sperm to return to normal.”

The Dangers Of Paternal Drinking

One of the major risks associated with alcohol consumption before and during pregnancy is FAS, which causes abnormal facial features, low birth weight and/or height, attention and hyperactivity issues, and poor coordination.

Currently, doctors are required to confirm only that the mother has consumed alcohol-not the father-to diagnose a child with FAS.

“For years, there’s really been no consideration of male alcohol use whatsoever,” Golding said. “Within the last five to eight years, we’ve started to notice that there are certain conditions where there’s a very strong paternal influence when it comes to alcohol exposure and fetal development.

“With this project, we wanted to see how long it would take for the effects of alcohol on sperm to wear off,” he said. “We thought it would be a relatively quick change back to normal, but it wasn’t. The withdrawal process took over a month.”

When drinking alcohol, an individual’s liver experiences oxidative stress, leading the body to overproduce certain chemicals, which then interrupts normal cellular activity. Golding’s team discovered that withdrawal causes the same kind of oxidative stress, effectively lengthening the duration of alcohol’s effects on the body beyond what was previously thought.

“During withdrawal, the liver experiences perpetual oxidative stress and sends a signal throughout the male body,” Golding said. “The reproductive system interprets that signal and says, ‘Oh, we are living in an environment that has a really strong oxidative stressor in it. I need to program the offspring to be able to adapt to that kind of environment.’ But Golding suspects that the adaptations to the sperm aren’t beneficial-they lead to problems like FAS.”

He also noted that it doesn’t take excessive alcohol use for a person to experience withdrawal.

“In the models we’re using, even drinking three to four beers after work several days a week can induce withdrawal when the behavior ceases,” Golding said. “You may not feel inebriated, but your body is going through chemical changes.”

Changing The Narrative

Golding’s work is vital to improving pregnancy outcomes by changing the conversation about who is responsible for alcohol-related birth defects, since society has historically placed all blame on mothers, even when they do not consume alcohol during their pregnancy.

“There’s psychological trauma associated with the question, ‘Did you drink while you were pregnant?’ It’s also difficult for physicians to have that conversation,” he said. “But if they don’t, then FAS doesn’t get diagnosed right away and the child may not get the support that they need until later in life.”

Because of this, it’s crucial that couples planning on getting pregnant know how far in advance to stop drinking in order to prevent birth defects.

While Golding and his lab will continue to research the effects of paternal drinking to help doctors advise couples, he suggests that fathers abstain from alcohol at least three months prior to conceiving, given this groundbreaking discovery.

“There’s still a lot of work to be done to get a hard answer, but we know that sperm are made over the course of 60 days, and the withdrawal process takes at least one month,” he said. “So, my estimate would be to wait at least three months.”

Reference:

Roach AN, Bhadsavle SS, Higgins SL, Derrico DD, Basel A, Thomas KN, Golding MC. Alterations in sperm RNAs persist after alcohol cessation and correlate with epididymal mitochondrial dysfunction. Andrology. 2023 Dec 3. doi: 10.1111/andr.13566. 

Powered by WPeMatico

AI accurately predicts malignancy on breast ultrasound, cuts down excessive follow-ups and biopsies

Turkey: A recent study published in Academic Radiology has shown the effectiveness of artificial intelligence (AI) to accurately predict malignancy on breast ultrasound based on BI-RADS (Breast Imaging-Reporting and Data System) assessment.

The study revealed that an AI method showed comparable performance to that of radiologists and can help avoid unnecessary biopsies and follow-up exams, which, in turn, can contribute to sustainability in healthcare practices.

“By considering AI-assigned BI-RADS 2 as safe, we could potentially avoid 11% of benign lesion biopsies and 46.2% of follow-ups,” Nilgun Guldogan, Breast Clinic, Acibadem Altunizade Hospital, Istanbul, Turkey, and colleagues reported.

Previous studies have shown increased use of artificial intelligence systems in breast ultrasonography. These studies have shown how AI aids in image interpretation, reduces false-positive cases, and potentially helps decrease the workload of radiologists. Therefore, Dr Guldogan and colleagues evaluated the performance of an AI system for the BI-RADS category assessment in breast masses detected on breast ultrasound.

For this purpose, the researchers analyzed 715 masses detected in 530 patients. Nine breast radiologists and three breast imaging centres of the same institution participated in the study. One radiologist performed an ultrasound and obtained two orthogonal views of each detected lesion. A second radiologist blinded to the patient’s clinical data retrospectively reviewed these images. The images were evaluated by a commercial AI system.

The level of agreement between the AI system and the two radiologists and their diagnostic performance were calculated according to dichotomic BI-RADS category assessment.

The study revealed the following findings:

· The study included 715 breast masses. Of these, 18.75% were malignant, and 81.25% were benign.

· The agreement between AI and the first and second radiologists was moderate statistically in discriminating benign and probably benign from suspicious lesions.

· The sensitivity and specificity of radiologist 1, radiologist 2, and AI were calculated as 98.51% and 80.72%, 97.76% and 75.56%, and 98.51% and 65.40%, respectively.

· For radiologist 1, the positive predictive value (PPV) was 54.10%, the negative predictive value (NPV) was 99.58%, and the accuracy was 84.06%.

· Radiologist 2 achieved a PPV of 47.99%, NPV of 99.32%, and accuracy of 79.72%.

· The AI system exhibited a PPV of 39.64%, NPV of 99.48%, and accuracy of 71.61%.

· None of the lesions categorized as BI-RADS 2 by AI were malignant, while 2 of the lesions classified as BI-RADS 3 by AI were subsequently confirmed as malignant.

· By considering AI-assigned BI-RADS 2 as safe, 11% of benign lesion biopsies and 46.2% of follow-ups could be potentially avoided.

“Artificial intelligence proves effective in predicting malignancy,” the researchers wrote, they added, “Integrating it into the clinical workflow has the potential to reduce short-term follow-ups and unnecessary biopsies, which, in turn, can contribute to sustainability in healthcare practices.”

Reference:

Guldogan, N., Taskin, F., Icten, G. E., Yilmaz, E., Turk, E. B., Erdemli, S., Parlakkilic, U. T., Turkoglu, O., & Aribal, E. (2023). Artificial Intelligence in BI-RADS Categorization of Breast Lesions on Ultrasound: Can We Omit Excessive Follow-ups and Biopsies? Academic Radiology. https://doi.org/10.1016/j.acra.2023.11.031

Powered by WPeMatico

Initiation of noninsulin second-line Antidiabetics fraught with risk of discontinuation within one year: Study

USA: Adherence to second-line diabetes drugs can be hit or miss among patients with type 2 diabetes, a recent study has reported.

The findings published in the American Journal of Managed Care showed that two-thirds of patients discontinued their medication, switched to a different medication class or intensified their treatment. Discontinuation was higher (50%) among glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs, which are linked to gastrointestinal side effects. 

When patients discontinue their medication, switch to a different drug or intensify their treatment (either via an increased dose, adding a third medication or starting insulin), it wastes the doctor and patient’s time, costs the health system unnecessary expense and, in the case of discontinuation, can result in a patient not fully treating their Type 2 diabetes.

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin — the go-to primary drug for glucose management — to control their blood sugar levels. 

The study of more than 82,000 patients between 2014 and 2017 found that within one year of their initial prescription, nearly two-thirds of patients either discontinued their medication, switched to a different medication class or intensified their treatment.

The scientists analyzed five non-insulin classes of diabetes medications. In four of the five classes, 38% of patients discontinued their medication. But among patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), half (50%) discontinued treatment.

“Discontinuation is bad. It is common in all five types of medications, but we see significantly more in those prescribed the GLP-1 RAs,” said corresponding author David Liss, research associate professor of general internal medicine at Northwestern University Feinberg School of Medicine.

“Presumably, the doctor is saying, ‘You need to start a new medication to control your Type 2 diabetes,’ and then within a year, half of them just stop and don’t start another one, and that’s not a good thing.”

Prior studies have shown that treatment discontinuation is common for Type 2 diabetes medications, but this is the first large American study to show such high discontinuation rates in second-line medications, Liss said.

“Our findings highlight the need for new prescribing approaches and to better understand the barriers patients face when taking these medications, to ultimately reduce wasting patients’ time, clinicians’ time and the health system’s money,” Liss said.

Association with gastrointestinal side effects

While the scientists did not have data on reasons why patients discontinued treatment, the particularly high discontinuation rate for GLP-1 RAs may have been due to adverse gastrointestinal side effects-such as nausea, vomiting and diarrhea-which have been observed in patients who take these medications for diabetes control and for weight loss, Liss said.

Originally approved by the U.S. Food and Drug Administration (FDA) for treating Type 2 diabetes, GLP-1 RAs (with brand names like Ozempic and Wegovy) are now used for weight loss, too. “We know there are gastrointestinal side effects for these drugs that are currently in the news, both for patients with diabetes and patients attempting to lose weight,” Liss said.

What happens after discontinuation?

For many patients in this study, discontinuing a second-line diabetes medication wouldn’t immediately lead to hyperglycemia (high blood sugar) symptoms or medical emergencies, Liss said.

“But discontinuation still puts these patients at greater risk for downstream hospitalizations related to diabetes,” Liss added.

Endocrinologist versus internal medicine prescribers

Discontinuation risk was lower and intensification risk was higher when an endocrinologist prescribed the medication, compared to when a family medicine or internal medicine physician prescribed the second-line drugs, the study found. Liss said this difference could be because endocrinologists had particular expertise in the newer classes of diabetes drugs, enhancing their ability to discuss the pros and cons of medications when making prescribing decisions with patients.

Importance of follow-ups on new drugs

The study retrospectively analyzed patients’ health insurance claims data, meaning the scientists could identify when a patient had been prescribed a medication; if the care provider switched their medication to a new class; or if they increased their dose.

The scientists assumed that patients who experienced a treatment switch or intensification did so after talking with their doctor. But the scientists suspect that many patients made the decision to discontinue their medication without having talked to a doctor.

“Our results may represent a ‘wake-up call’ for clinicians that many of their patients were not taking the medicines that were prescribed,” Liss said. “While we don’t know if providers were aware of the discontinuation events observed in this study, our results highlight the need for ongoing communication between patients and prescribers over time-around medication benefits, side effects and costs-not just at the time of prescribing.” 

Reference:

David T. Liss, Manisha Cherupally, Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes, The American Journal of Managed Care, DOI: 10.37765/ajmc.2023.89466

Powered by WPeMatico

Efficacy and Mechanisms of Midazolam in Inhibiting Cancer Progression

Researchers have found in a new study that  midazolam has the potential to impede cancer progression and decrease cancer cell survival. The new systematic review has been published in the Indian Journal of Anaesthesia. 

The systematic review evaluated the potential role of midazolam in inhibiting cancer progression and reducing cancer cell survival. The review included 19 preclinical studies, which predominantly focused on in vitro experiments and some combination of in vitro and in vivo studies. The findings suggested that midazolam demonstrated potential anticancer properties, as it delayed cancer progression in 89% of the studies and reduced cancer cell survival in 63% of the studies. These effects were attributed to midazolam’s ability to induce apoptosis and inhibit cancer cell proliferation, with demonstrated antimetastatic properties. The review also highlighted that midazolam might alter the efficacy of traditional anticancer agents, such as chemotherapy and immunotherapy. However, it noted that the mechanisms underlying these effects remain unclear due to the short-term nature of the in vitro and in vivo studies.

Limitations and Recommendations for Further Studies on Midazolam’s Role in Cancer

The paper acknowledged conflicting literature on midazolam’s role in cancer progression and the need for further investigation into its potential clinical implications. It highlighted the limitations of the included studies, such as the absence of clinical context, variability in experimental protocols and the need for additional clinical research to determine the appropriate dosage and assess the efficacy and safety of midazolam. The review recommended future studies to investigate the mechanisms underlying midazolam’s effects on tumor growth and interactions with other cancer treatments. It also called for clinical trials to evaluate the impact of midazolam on cancer outcomes in patients undergoing cancer surgery or related procedures.

Conclusion of the Systematic Review on Midazolam’s Potential in Cancer Therapy

In summary, the systematic review suggested that midazolam has the potential to impede cancer progression and decrease cancer cell survival based on preclinical evidence, although its clinical relevance and application require further investigation.

Reference –

Sethi, Ansh†; Rezk, Amal1,†; Couban, Rachel2; Chowdhury, Tumul1. Role of midazolam on cancer progression/survival – An updated systematic review. Indian Journal of Anaesthesia 67(11):p 951-961, November 2023. | DOI: 10.4103/ija.ija_731_23 

Powered by WPeMatico

Adjunctive Antimicrobial peptide clinically effective for stage III grade B periodontitis

Adjunctive antimicrobial peptide was clinically efficacious for treatment of stage III grade B periodontitis suggests a new study published in the Oral Diseases.

A study was conducted to evaluate the effects of antimicrobial peptides (AMPs) on Stage III Grade B periodontitis.

This trial abided by the principle of consistency test, approved by ethics committee and registered in clinical trials. All qualified 51 patients with Stage III Grade B periodontitis were randomly divided into three groups: SRP group, SRP with minocycline hydrochloride (Mino group) as Control groups, and SRP with AMPs (AMP group) as the Test group. Clinical examinations and subgingival plaques were monitored at baseline and at 7 and 90 days after treatment in the SRP, SRP with AMP and Mino groups.

Results

The antimicrobial peptides (AMPs) group (Test group) had a reduced PD (Periodontal probing depth) and an attachment gain significantly higher than SRP and Mino groups (Control groups) at day 90. The abundance of periodontal pathogens was decreased in the AMP group at 7 and 90 days compared with the SRP group and Mino group. Only the antimicrobial peptides (AMPs) group showed an increase the abundance of periodontal probiotics including Capnocytophaga, Gemella, and Lactobacillus at 7 and 90 days.

This study shows that antimicrobial peptides (AMPs) as an adjunct to SRP promote additional clinical and microbiological benefits in the treatment of Stage III Grade B periodontitis.

The clinical efficacy of the adjunctive topical use of AMPs in the treatment of stage III grade B periodontitis is better than that of the adjunctive topical use of minocycline hydrochloride and mechanical treatment only. AMPs are more conducive to the transformation of the subgingival microecosystem to a healthy subgingival microecosystem, rather than simply killing the periodontal bacteria.

Reference:

Xiang, S., Han, N., Xie, Y., Du, J., Luo, Z., Xu, J., & Liu, Y. (2023). Antimicrobial peptides in treatment of Stage III Grade B periodontitis: A randomized clinical trial. Oral Diseases, 00, 1–10. https://doi.org/10.1111/odi.14786

Keywords:

Adjunctive, antimicrobial, peptide, clinically, efficacious, for, treatment, stage III, grade B, periodontitis, Xiang, S., Han, N., Xie, Y., Du, J., Luo, Z., Xu, J., & Liu, Y, Oral Diseases

Powered by WPeMatico